129 related articles for article (PubMed ID: 31473819)
21. Effects of sustained antiangiogenic therapy in multistage prostate cancer in TRAMP model.
Isayeva T; Chanda D; Kallman L; Eltoum IE; Ponnazhagan S
Cancer Res; 2007 Jun; 67(12):5789-97. PubMed ID: 17575146
[TBL] [Abstract][Full Text] [Related]
22. Antiangiogenic therapy effects on age-associated matrix metalloproteinase-9 (MMP-9) and insulin-like growth factor receptor-1 (IGFR-1) responses: a comparative study of prostate disorders in aged and TRAMP mice.
Montico F; Kido LA; Hetzl AC; Lorencini RM; Cândido EM; Cagnon VH
Histochem Cell Biol; 2014 Sep; 142(3):269-84. PubMed ID: 24562790
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.
Diaz R; Nguewa PA; Redrado M; Manrique I; Calvo A
Prostate; 2015 Aug; 75(11):1137-49. PubMed ID: 25893276
[TBL] [Abstract][Full Text] [Related]
24. Preclinical Evaluation of Nintedanib, a Triple Angiokinase Inhibitor, in Soft-tissue Sarcoma: Potential Therapeutic Implication for Synovial Sarcoma.
Patwardhan PP; Musi E; Schwartz GK
Mol Cancer Ther; 2018 Nov; 17(11):2329-2340. PubMed ID: 30166401
[TBL] [Abstract][Full Text] [Related]
25. Angiotensin-(1-7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1.
Krishnan B; Torti FM; Gallagher PE; Tallant EA
Prostate; 2013 Jan; 73(1):60-70. PubMed ID: 22644934
[TBL] [Abstract][Full Text] [Related]
26. Nintedanib modulates surfactant protein-D expression in A549 human lung epithelial cells via the c-Jun N-terminal kinase-activator protein-1 pathway.
Kamio K; Usuki J; Azuma A; Matsuda K; Ishii T; Inomata M; Hayashi H; Kokuho N; Fujita K; Saito Y; Miya T; Gemma A
Pulm Pharmacol Ther; 2015 Jun; 32():29-36. PubMed ID: 25843005
[TBL] [Abstract][Full Text] [Related]
27. Nintedanib: A Review of Its Use as Second-Line Treatment in Adults with Advanced Non-Small Cell Lung Cancer of Adenocarcinoma Histology.
Dhillon S
Target Oncol; 2015 Jun; 10(2):303-10. PubMed ID: 25894578
[TBL] [Abstract][Full Text] [Related]
28. Multiple receptor tyrosine kinases regulate HIF-1alpha and HIF-2alpha in normoxia and hypoxia in neuroblastoma: implications for antiangiogenic mechanisms of multikinase inhibitors.
Nilsson MB; Zage PE; Zeng L; Xu L; Cascone T; Wu HK; Saigal B; Zweidler-McKay PA; Heymach JV
Oncogene; 2010 May; 29(20):2938-49. PubMed ID: 20208561
[TBL] [Abstract][Full Text] [Related]
29. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer.
Adhami VM; Siddiqui IA; Ahmad N; Gupta S; Mukhtar H
Cancer Res; 2004 Dec; 64(23):8715-22. PubMed ID: 15574782
[TBL] [Abstract][Full Text] [Related]
30. Epigallocatechin-3-Gallate suppresses early stage, but not late stage prostate cancer in TRAMP mice: mechanisms of action.
Harper CE; Patel BB; Wang J; Eltoum IA; Lamartiniere CA
Prostate; 2007 Oct; 67(14):1576-89. PubMed ID: 17705241
[TBL] [Abstract][Full Text] [Related]
31. Nintedanib in non-small cell lung cancer: from preclinical to approval.
Caglevic C; Grassi M; Raez L; Listi A; Giallombardo M; Bustamante E; Gil-Bazo I; Rolfo C
Ther Adv Respir Dis; 2015 Aug; 9(4):164-72. PubMed ID: 25855060
[TBL] [Abstract][Full Text] [Related]
32. Long pentraxin-3 as an epithelial-stromal fibroblast growth factor-targeting inhibitor in prostate cancer.
Ronca R; Alessi P; Coltrini D; Di Salle E; Giacomini A; Leali D; Corsini M; Belleri M; Tobia C; Garlanda C; Bonomi E; Tardanico R; Vermi W; Presta M
J Pathol; 2013 Jun; 230(2):228-38. PubMed ID: 23424081
[TBL] [Abstract][Full Text] [Related]
33. 3,3'-Diindolylmethane inhibits prostate cancer development in the transgenic adenocarcinoma mouse prostate model.
Cho HJ; Park SY; Kim EJ; Kim JK; Park JH
Mol Carcinog; 2011 Feb; 50(2):100-12. PubMed ID: 21229607
[TBL] [Abstract][Full Text] [Related]
34. Vernolide-A inhibits radiation-induced hypoxia-mediated tumor angiogenesis by regulating HIF-1α, MMP-2, MMP-9, and VEGF.
Pratheeshkumar P; Kuttan G
J Environ Pathol Toxicol Oncol; 2011; 30(2):139-51. PubMed ID: 21967458
[TBL] [Abstract][Full Text] [Related]
35. A novel antisense inhibitor of MMP-9 attenuates angiogenesis, human prostate cancer cell invasion and tumorigenicity.
London CA; Sekhon HS; Arora V; Stein DA; Iversen PL; Devi GR
Cancer Gene Ther; 2003 Nov; 10(11):823-32. PubMed ID: 14605668
[TBL] [Abstract][Full Text] [Related]
36. Nintedanib for the treatment of non-small-cell lung cancer.
Rashdan S; Hanna N
Expert Opin Pharmacother; 2014 Apr; 15(5):729-39. PubMed ID: 24597846
[TBL] [Abstract][Full Text] [Related]
37. Adenocarcina of the mouse prostate growth inhibition by celecoxib: downregulation of transcription factors involved in COX-2 inhibition.
Narayanan BA; Narayanan NK; Pttman B; Reddy BS
Prostate; 2006 Feb; 66(3):257-65. PubMed ID: 16175586
[TBL] [Abstract][Full Text] [Related]
38. The potential role of nintedanib in treating colorectal cancer.
Rossi A; Latiano TP; Parente P; Chiarazzo C; Limosani F; Di Maggio G; Maiello E
Expert Opin Pharmacother; 2017 Aug; 18(11):1153-1162. PubMed ID: 28649871
[TBL] [Abstract][Full Text] [Related]
39. Terrestrosin D, a steroidal saponin from Tribulus terrestris L., inhibits growth and angiogenesis of human prostate cancer in vitro and in vivo.
Wei S; Fukuhara H; Chen G; Kawada C; Kurabayashi A; Furihata M; Inoue K; Shuin T
Pathobiology; 2014; 81(3):123-32. PubMed ID: 24642631
[TBL] [Abstract][Full Text] [Related]
40. Fibroblast growth factor 2 promotes tumor progression in an autochthonous mouse model of prostate cancer.
Polnaszek N; Kwabi-Addo B; Peterson LE; Ozen M; Greenberg NM; Ortega S; Basilico C; Ittmann M
Cancer Res; 2003 Sep; 63(18):5754-60. PubMed ID: 14522896
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
